id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-347662-yk3cz0hq	Li, Michael	Tocilizumab in the Management of COVID-19: A Preliminary Report	2020-11-09		.txt	text/plain	3300	171	40	EXPOSURES: Confirmed COVID-19 pneumonia MAIN OUTCOMES AND MEASURES: Outcomes data related to length of stay, admission to intensive care unit (ICU), requirement of mechanical ventilation, and mortality were collected and analyzed. CONCLUSION AND RELEVANCE: Our retrospective analysis revealed an association between Tocilizumab administration and increased mortality, ICU admission, mechanical ventilation, and length of stay in subjects with COVID-19. On this basis, physicians at our hospitals have administered Tocilizumab to COVID-19 patients with severe respiratory impairment off-label and outside of a clinical trial hoping to improve outcomes by preventing or ameliorating the development or progression of the COVID-19 related cytokine storm, thereby inhibiting the development of ARDS in both the intensive care unit (ICU) and non-ICU settings. Criteria for inclusion in the Tocilizumab treatment group included: 1) age of 18 years or older with a clinical presentation consistent with COVID-19 (e.g., fever, respiratory symptoms, and new pulmonary infiltrates), 2) laboratory confirmation of SARS-CoV-2 infection by an RT-PCR test, and 3) outcome data available.	./cache/cord-347662-yk3cz0hq.txt	./txt/cord-347662-yk3cz0hq.txt